EN
SINOVAC Honored "MITRA BUMN GLOBAL CHAMPION 2022" for its success collaborating with Indonesia's SOEs to supply the COVID-19 vaccine
May 9, 2022 – Jakarta, Indonesia – SINOVAC Biotech Ltd., (SINOVAC), a leading provider of biopharmaceutical products in China, has been honored with the "MITRA BUMN GLOBAL CHAMPION 2022" award from the Indonesia State Ministry for State-Owned Enterprises (SOE). The award recognizes SINOVAC's contributions while serving as a partner to Indonesia's SOEs and success helping Indonesia produce and supply the COVID-19 vaccine during the pandemic.
SINOVAC Country Head of Indonesia received the award
SINOVAC, the only biopharmaceutical company to be awarded, has provided Indonesia with more than 280 million doses of its CoronaVac® COVID-19 vaccine. Of these, more than 100 million doses were delivered in semi-manufactured form, and filled and packaged by the Indonesian SOE, Bio Farma, to supply the Indonesia government's immunization programs.
The Indonesia State Ministry for SOEs delivered the award during an award ceremony, held today with the aim of strengthening synergy between Indonesia's SOEs and the private sector to encourage national economic development.
"The synergy between the lines, both from SOEs and private sectors is very important in building the nation's independence," said Erick Thohir, minister of SOEs. "Especially amid an era of uncertainty due to the pandemic, which disrupted the supply chain."
To ensure the national supply of COVID-19 vaccine in Indonesia, SINOVAC and Bio Farma reached a joint production agreement on Aug. 20, 2021, making SINOVAC the first company to cooperate with the SOE. In January 2021, the SINOVAC CoronaVac® COVID-19 vaccine was the first to be approved by the Indonesian government for emergency use and halal certification. On Jan. 13, 2021, Joko Widodo, president of Indonesia, became the first person in Indonesia to be vaccinated. With his first dose of CoronaVac®, he kicked off the nation's mass public vaccination.
In February 2021, Indonesia approved CoronaVac® for the elderly and in November 2021 it was approved for children aged 6 to 11, the only vaccine approved for use in this age group.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Paneflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.